Publication: Pharmacogenomics: A new approach for preventing severe cutaneous adverse drug reactions
Issued Date
2018-07-02
Resource Type
Other identifier(s)
2-s2.0-85063186796
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Genomics-Driven Healthcare: Trends in Disease Prevention and Treatment. (2018), 373-409
Suggested Citation
Chonlaphat Sukasem, Therdpong Tempark Pharmacogenomics: A new approach for preventing severe cutaneous adverse drug reactions. Genomics-Driven Healthcare: Trends in Disease Prevention and Treatment. (2018), 373-409. doi:10.1007/978-981-10-7506-3_18 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/46518
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Pharmacogenomics: A new approach for preventing severe cutaneous adverse drug reactions
Author(s)
Other Contributor(s)
Abstract
© Springer Nature Singapore Pte Ltd. 2018. Pharmacogenomics can be used to identify genetic predisposing factors for serious cutaneous adverse reactions and personalize drug therapy accordingly. Pharmacogenetic screening for severe cutaneous adverse reactions (SCARs) is a key opportunity and potential paradigm for reducing morbidity and mortality and finally eliminating some of the most devastating of adverse drug reactions. This chapter focuses on the current state of surveillance know-how, pathogenesis, and treatment of SCARs. The role of genomics and pharmacogenomics in the etiology, treatment, and eradication of preventable causes of drug-induced SCARs is discussed. Drugs associated with hypersensitivity reactions with strong genetic predisposing factors include abacavir, nevirapine, carbamazepine, allopurinol, etc. The gaps, unmet needs, and priorities for future research are identified in order to eliminate genetically mediated SCARs globally.